Prostate cancer has distinct genetic properties in different groups of men that could be targeted to improve patient outcomes, new research suggests.

In Anchorage, Providence Alaska Medical Center has become the first facility in the state to offer an innovative treatment for metastatic prostate cancer. In March, the hospital began administering ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Prostate cancer remains one of the most significant health concerns for men worldwide, with detection and treatment options ...

Pedro C. Barata, MD, MSc, discusses the use of darolutamide in patients with hormone-sensitive prostate cancer.

Alexander Kenigsberg, MD, discusses a new nonsurgical, robotic-focused ultrasound procedure for prostate cancer.

Most women with breast cancer who paused endocrine therapy for pregnancy did not resume. These women had a higher rate of breast recurrence and death than expected. Most women with breast cancer ...

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

The phase 2a LEGION-100 trial seeks to evaluate the safety and effectiveness of the SYNC-T/SV-102 combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC) and to ...

• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...